Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239–57.

Article  PubMed  Google Scholar 

Kim S, Han Y, Kim SI, Kim HS, Kim SJ, Song YS. Tumor evolution and chemoresistance in ovarian cancer. NPJ Precis Oncol. 2018;2:20.

Article  PubMed  PubMed Central  Google Scholar 

Li X, Ng ASN, Mak VCY, Chan KKL, Cheung ANY, Cheung LWT. Strategic combination therapies for ovarian cancer. Curr Cancer Drug Targets. 2020;20(8):573–85.

Article  CAS  PubMed  Google Scholar 

Tendulkar S, Dodamani S. Chemoresistance in ovarian cancer: prospects for new drugs. Anticancer Agents Med Chem. 2021;21(6):668–78.

Article  CAS  PubMed  Google Scholar 

Hirschey MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, Jones LW, Ko YH, Le A, Lea MA, et al. Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol. 2015;35(Suppl):S129–50.

Article  PubMed  Google Scholar 

DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.

Article  PubMed  PubMed Central  Google Scholar 

Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nayak AP, Kapur A, Barroilhet L, Patankar MS. Oxidative phosphorylation: a target for novel therapeutic strategies against ovarian cancer. Cancers (Basel). 2018;10(9):337.

Article  PubMed  Google Scholar 

Ma L, Zong X. Metabolic symbiosis in chemoresistance: refocusing the role of aerobic glycolysis. Front Oncol. 2020;10:5.

Article  PubMed  PubMed Central  Google Scholar 

Sato M, Kawana K, Adachi K, Fujimoto A, Yoshida M, Nakamura H, Nishida H, Inoue T, Taguchi A, Takahashi J, et al. Spheroid cancer stem cells display reprogrammed metabolism and obtain energy by actively running the tricarboxylic acid (TCA) cycle. Oncotarget. 2016;7(22):33297–305.

Article  PubMed  PubMed Central  Google Scholar 

Ding Y, Labitzky V, Legler K, Qi M, Schumacher U, Schmalfeldt B, Sturken C, Oliveira-Ferrer L. Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer. Mol Oncol. 2021;15(12):3578–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pendleton KE, Wang K, Echeverria GV. Rewiring of mitochondrial metabolism in therapy-resistant cancers: permanent and plastic adaptations. Front Cell Dev Biol. 2023;11:1254313.

Article  PubMed  PubMed Central  Google Scholar 

Hu B, Guo Y. Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance. Biochem Biophys Res Commun. 2019;509(2):373–8.

Article  CAS  PubMed  Google Scholar 

Pasto A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi M, Guzzo G, Rasola A, Frasson C, Nardo G, Zulato E, et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 2014;5(12):4305–19.

Article  PubMed  PubMed Central  Google Scholar 

Dar S, Chhina J, Mert I, Chitale D, Buekers T, Kaur H, Giri S, Munkarah A, Rattan R. Bioenergetic adaptations in chemoresistant ovarian cancer cells. Sci Rep. 2017;7(1):8760.

Article  PubMed  PubMed Central  Google Scholar 

Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482–90.

Article  CAS  PubMed  Google Scholar 

Neitzel C, Demuth P, Wittmann S, Fahrer J. Targeting altered energy metabolism in colorectal cancer: oncogenic reprogramming, the central role of the TCA cycle and therapeutic opportunities. Cancers (Basel). 2020;12(7):1731.

Article  CAS  PubMed  Google Scholar 

Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, et al. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014;20(20):5255–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellio C, DiGloria C, Spriggs DR, Foster R, Growdon WB, Rueda BR. The metabolic inhibitor CPI-613 negates treatment enrichment of ovarian cancer stem cells. Cancers (Basel). 2019;11(11):1678.

Article  CAS  PubMed  Google Scholar 

Kumstel S, Schreiber T, Goldstein L, Stenzel J, Lindner T, Joksch M, Zhang X, Wendt EHU, Schönrogge M, Krause B, et al. Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. PLoS ONE. 2022;17(4):e0266601.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zachar Z, Marecek J, Maturo C, Gupta S, Stuart SD, Howell K, Schauble A, Lem J, Piramzadian A, Karnik S, et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl). 2011;89(11):1137–48.

Article  CAS  PubMed  Google Scholar 

Gao L, Xu Z, Huang Z, Tang Y, Yang D, Huang J, He L, Liu M, Chen Z, Teng Y. CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling. J Exp Clin Cancer Res. 2020;39(1):73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khan HY, Kamgar M, Aboukameel A, Bannoura S, Chung BY, Li Y, Hallak MNA, Philip PA, Tsai S, Luther S, et al. Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiation therapy. Adv Radiat Oncol. 2023;8(1):101122.

Article  CAS  PubMed  Google Scholar 

Lang L, Wang F, Ding Z, Zhao X, Loveless R, Xie J, Shay C, Qiu P, Ke Y, Saba NF, et al. Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer. J Exp Clin Cancer Res. 2021;40(1):393.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Egawa Y, Saigo C, Kito Y, Moriki T, Takeuchi T. Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma. PLoS ONE. 2018;13(6):e0198940.

Article  PubMed  PubMed Central  Google Scholar 

Arnold C, Demuth P, Seiwert N, Wittmann S, Boengler K, Rasenberger B, Christmann M, Huber M, Brunner T, Linnebacher M, et al. The mitochondrial disruptor devimistat (CPI-613) synergizes with Genotoxic Anticancer drugs in Colorectal Cancer Therapy in a bim-dependent manner. Mol Cancer Ther. 2022;21(1):100–12.

Article  CAS  PubMed  Google Scholar 

Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D’Agostino R Jr., Topaloglu U, et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017;18(6):770–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardee TS, Luther S, Buyse M, Powell BL, Cortes J. Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. Future Oncol. 2019;15(28):3197–208.

Article  CAS  PubMed